will need to verify that the drug is working, and is not causing undesirable side effects. A bone density screening may also be appropriate for women withosteoporosis, or those who are at risk for the disease, as this drug can cause a loss of bone density, or it may worsen the ...
Murai, K.; Yamazaki, H.; Nakagawa, K.; Kawai, R.; Kamataki, T. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 2009, 39, 795-802. [CrossRef] [PubMed]...
Orlistat, an anti-obesity drug approved by the U.S. FDA, has been used to improve or reverse the pathological characteristics of PCOS [20]. Kumar et al. found that orlistat in PCOS is as effective as metformin in reducing weight with improvement in the lipid profile and pregnancy rates [...
after at least 4 months of therapy (while still on second drug and prior to final surgery). 2.5. Aro-ER tri-screen The AroER tri-screen [20] was used to measure the total estrogenic activity in human serum samples obtained during the NEOLETEXE-trial. This analysis was approved by the ...
Conclusion: One-year neoadjuvant letrozole therapy leads to a higher pathCR rate and may be the optimal length of drug exposure. *Correspondence: Dr D Generali; E-mail: daniele.generali@gmail.com Received 14 January 2013; revised 1 March 2013; accepted 7 March 2013; published online 11 April...
Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial Diabetes care, 34 (7) (2011), pp. 1591-1594 CrossrefView in ScopusGoogle Scholar [24] C. Li, L. Chen, Y. Zhao, S. Chen, L. Fu, Y. Jiang, S....
1. Disease-free Survival (DFS);5-year estimates, reported at a median follow-up of 60 months;Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional...
The severity of AEs was classified in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE version 3.0). AEs were documented during the period from first exposure to the study drug to 30 days after last exposure to it. Adverse events, ...
Tumor lysis syndrome (TLS) is a complication that can trigger multiple organ failure caused by the release of intracellular nucleic acids, phosphate, and potassium into the blood due to rapid tumor cell disintegration induced by drug therapy. TLS is uncommon in solid tumors and occurs primarily ...
doi:10.1007/s40261-023-01305-3Luis,FeinNicolas,LazarettiYamil López,ChukenJ. Rogelio González Ramírez,BenfieldMax S.,ManoJose,LobatonErnesto,KorbenfeldFernanda,DamianDongrui R.,LuAve,MoriSpringer International PublishingClinical drug investigation...